Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21.

IF 3.8 3区 医学 Q2 GERIATRICS & GERONTOLOGY Drugs & Aging Pub Date : 2024-06-01 Epub Date: 2024-06-17 DOI:10.1007/s40266-024-01123-y
Michael T Lynskey, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne K Schlag, David J Nutt
{"title":"Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21.","authors":"Michael T Lynskey, Hannah Thurgur, Alkyoni Athanasiou-Fragkouli, Anne K Schlag, David J Nutt","doi":"10.1007/s40266-024-01123-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Previous research has suggested that the use of cannabis-based medicinal products is increasing most rapidly among older aged individuals (65+ years). Despite this, little is known about the characteristics of older people using cannabis-based medicinal products and their effectiveness.</p><p><strong>Objectives: </strong>We aimed to document the characteristics, outcomes and prescribing patterns of individuals aged 65+ years receiving prescribed cannabis compared to younger individuals receiving prescribed cannabis.</p><p><strong>Methods: </strong>Data from T21, an observational study of patients seeking treatment with medicinal cannabinoids, including self-report ratings of quality of life (assessed via the EQ-5D-5L), general health (assessed via the visual analogue scale of the EQ-5D-5L), mood (assessed via the Patient Health Questionnaire-9) and sleep (assessed using four items derived from the Pittsburgh Sleep Quality Index) were available at treatment entry [n = 4228; 198 (4.7%) 65+ years] and at a 3-month follow-up [n = 2455; 98 (4.2%) = 65+ years].</p><p><strong>Results: </strong>Relative to younger individuals, those aged over 64 years were more likely to be female (52.5% vs 47.0%; p < 0.001), more likely to report pain as their primary condition (76.3% vs 45.6%; p < 0.001) and less likely to report current daily use (20.2% vs 60.3%, p < 0.001). They received fewer cannabis-based medicinal products (mean = 1.4 vs 2.1; F<sub>(1,2199)</sub> = 32.3, p < 0.001) and were more likely to receive a prescription for a cannabidiol dominant oil (17.5% vs 5.7%; p < 0.001) and less likely to receive a prescription for delta-9-tetrahydrocannabinol dominant flower (32.5% vs 75.2%; p < 0.001). There were significant improvements across all measures of well-being (p < 0.001), but the extent of improvements in sleep were more marked in younger individuals (p < 0.001).</p><p><strong>Conclusions: </strong>There are important differences between individuals aged 65+ years and younger individuals receiving cannabis-based medicinal products. Older aged individuals experience considerable improvement in health and well-being when prescribed cannabis-based medicinal products.</p>","PeriodicalId":11489,"journal":{"name":"Drugs & Aging","volume":" ","pages":"521-530"},"PeriodicalIF":3.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drugs & Aging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40266-024-01123-y","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Previous research has suggested that the use of cannabis-based medicinal products is increasing most rapidly among older aged individuals (65+ years). Despite this, little is known about the characteristics of older people using cannabis-based medicinal products and their effectiveness.

Objectives: We aimed to document the characteristics, outcomes and prescribing patterns of individuals aged 65+ years receiving prescribed cannabis compared to younger individuals receiving prescribed cannabis.

Methods: Data from T21, an observational study of patients seeking treatment with medicinal cannabinoids, including self-report ratings of quality of life (assessed via the EQ-5D-5L), general health (assessed via the visual analogue scale of the EQ-5D-5L), mood (assessed via the Patient Health Questionnaire-9) and sleep (assessed using four items derived from the Pittsburgh Sleep Quality Index) were available at treatment entry [n = 4228; 198 (4.7%) 65+ years] and at a 3-month follow-up [n = 2455; 98 (4.2%) = 65+ years].

Results: Relative to younger individuals, those aged over 64 years were more likely to be female (52.5% vs 47.0%; p < 0.001), more likely to report pain as their primary condition (76.3% vs 45.6%; p < 0.001) and less likely to report current daily use (20.2% vs 60.3%, p < 0.001). They received fewer cannabis-based medicinal products (mean = 1.4 vs 2.1; F(1,2199) = 32.3, p < 0.001) and were more likely to receive a prescription for a cannabidiol dominant oil (17.5% vs 5.7%; p < 0.001) and less likely to receive a prescription for delta-9-tetrahydrocannabinol dominant flower (32.5% vs 75.2%; p < 0.001). There were significant improvements across all measures of well-being (p < 0.001), but the extent of improvements in sleep were more marked in younger individuals (p < 0.001).

Conclusions: There are important differences between individuals aged 65+ years and younger individuals receiving cannabis-based medicinal products. Older aged individuals experience considerable improvement in health and well-being when prescribed cannabis-based medicinal products.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年人处方医用大麻的使用:患者特征和福祉改善:T21 的研究结果。
背景:以往的研究表明,大麻药用产品的使用在老年人(65 岁以上)中增长最快。尽管如此,人们对使用大麻药用产品的老年人的特点及其有效性知之甚少:我们旨在记录 65 岁以上接受处方大麻的人与接受处方大麻的年轻人相比的特征、结果和处方模式:方法:T21 是一项针对寻求使用药用大麻素治疗的患者的观察性研究,其数据包括患者在开始治疗时对生活质量(通过 EQ-5D-5L 进行评估)、一般健康状况(通过 EQ-5D-5L 的视觉模拟量表进行评估)、情绪(通过患者健康问卷-9 进行评估)和睡眠(通过源自匹兹堡睡眠质量指数的四个项目进行评估)的自我报告评分[n = 4228;198(4.结果:与年轻人相比,64 岁以上的老年人更可能是女性(52.5% 对 47.0%;p < 0.001),更可能报告疼痛是他们的主要病症(76.3% 对 45.6%;p < 0.001),更不可能报告目前每天使用大麻(20.2% 对 60.3%,p < 0.001)。他们获得的大麻类药用产品较少(平均值 = 1.4 vs 2.1;F(1,2199) = 32.3,p < 0.001),更有可能获得以大麻二酚为主的大麻油处方(17.5% vs 5.7%;p < 0.001),而获得以δ-9-四氢大麻酚为主的大麻花处方的可能性较小(32.5% vs 75.2%;p < 0.001)。所有幸福感指标均有明显改善(p < 0.001),但睡眠改善程度在年轻人中更为明显(p < 0.001):接受大麻药用产品治疗的 65 岁以上老年人和年轻人之间存在重大差异。老年人在服用大麻药用产品后,其健康和福祉会得到显著改善。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Drugs & Aging
Drugs & Aging 医学-老年医学
CiteScore
5.50
自引率
7.10%
发文量
68
审稿时长
6-12 weeks
期刊介绍: Drugs & Aging delivers essential information on the most important aspects of drug therapy to professionals involved in the care of the elderly. The journal addresses in a timely way the major issues relating to drug therapy in older adults including: the management of specific diseases, particularly those associated with aging, age-related physiological changes impacting drug therapy, drug utilization and prescribing in the elderly, polypharmacy and drug interactions.
期刊最新文献
Association Between Anticholinergic Burden and Dry Mouth Severity in Acutely Ill Older Adults. Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye. Efficacy and Safety of DOACs in Patients with Atrial Fibrillation and History of Falls or Risk of Falls: The Liverpool AF-Falls Project. A Systematic Review and Bayesian Network Meta-analysis. Managing Bone Fragility in Older Adults with Diabetes: Pathophysiology, Assessment, and Therapeutic Considerations. Investigating Potential Prescribing Cascades Resulting in Prochlorperazine Prescription: An Exploratory Analysis of Antihypertensives and NSAIDs.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1